InnoCare announces approval of clinical trial of a novel ADC ICP-B794 in China

Iksuda Therapeutics receives FDA IND clearance for IKS014

Huadong Medicine’s first-in-class ADC HDM2012 gains FDA Phase I trial clearance

Elevation Oncology ends license agreement with CSPC Megalith Biopharmaceutical

Biokin, having landed BMS deal, posts Phase 3 cancer win for bispecific ADC

Akeso’s first bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials, strengthening leadership in ‘IO+ADC’ 2.0 strategy